MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/bmjopen-2025-103766

Медицинская библиотека · BMJ open · 2026

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in large- or small-vessel disease ischaemic stroke in the USA.

Reynolds Matthew R, Pollit Vicki, Schwamm Lee, Witte Klaus K, Yaghi Shadi, Rose David Z, Cudworth Sarah, Carpenter Julius, Rosemas Sarah C, Ziegler Paul D, Neisen Karah, Franco Noreli C, Bernstein Richard A

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

To evaluate the cost-effectiveness of insertable cardiac monitors (ICMs) compared to standard of care (SoC) to detect atrial fibrillation (AF) in patients with stroke of presumed known cause of large-artery atherosclerotic disease (LAD) or small-vessel occlusive disease (SVD) from a US payer perspective.

DESIGN

A lifetime Markov model assessed cost-effectiveness of ICM versus SoC from a US payer perspective. Patient characteristics and AF detection rates were based on the STROKE AF trial (NCT02700945): 3-year diagnostic yield was 21.7% (95% CI 16.7% to 27.9%) for ICM and 2.4% (1.0%-5.7%) for SoC. AF detection resulted in a switch from aspirin to direct oral anticoagulant unless precluded by prior bleeding. Subsequent risks of ischaemic strokes (ISs) and bleeding events were modelled based on published literature. Costs and effects were discounted at 3% annually. Specific SoC short-term monitoring strategies (STMs) were explored as scenarios.

SETTING

US healthcare system perspective.

PARTICIPANTS

Hypothetical cohort of patients with IS believed to be due to LAD or SVD.

INTERVENTIONS: Patients received an ICM within ten days of the index stroke or SoC involving conventional follow-up.

MAIN OUTCOME MEASURES: Stroke and bleeding risk, mortality, health-related quality of life and healthcare cost and utilisation.

RESULTS

ICM was associated with a gain of 0.176 quality-adjusted life years (QALYs) compared with SoC per patient, representing a reduction of 53 strokes per 1000 patients. The lifetime incremental cost of ICM was $6736 per patient. This resulted in an estimated incremental cost-effectiveness ratio (ICER) of $38 346 per QALY gained, making ICM a cost-effective intervention at willingness-to-pay thresholds of $50 000-$150 000 per QALY in the USA. ICMs were also cost-effective compared with various individual STMs, with ICERs ranging from $29 814 to $38 941 per QALY gained. The mean probabilistic ICER across 5000 samples was $46 910 per QALY (97.5% CI$45 421 to $53 523). Results were sensitive to anticoagulant uptake on AF detection and underlying stroke risk. Model findings were robust to both probabilistic sensitivity analysis and sensitivity analyses where inputs tested were considered within plausible ranges, as ICM was found cost-effective in these analyses.

CONCLUSIONS

ICMs are highly likely to be a cost-effective diagnostic tool for secondary prevention of stroke related to AF in US patients with prior stroke attributed to LAD or SVD. However, further research is needed to understand the efficacy of secondary stroke prevention treatments in patients with stroke attributed to LAD or SVD and subclinical AF.

Для цитирования: Reynolds Matthew R, Pollit Vicki, Schwamm Lee, Witte Klaus K, Yaghi Shadi, Rose David Z, Cudworth Sarah, Carpenter Julius, Rosemas Sarah C, Ziegler Paul D, Neisen Karah, Franco Noreli C, Bernstein Richard A. Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in large- or small-vessel disease ischaemic stroke in the USA.. BMJ open. 2026. DOI: 10.1136/bmjopen-2025-103766.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.